VisionGate is dedicated to saving lives through early disease detection. VisionGate’s first commercial product, LuCED®, focuses on the #1 cancer killer – lung cancer. LuCED is a non-invasive test to aid physicians in the early detection of lung cancer utilizing sputum (phlegm). VisionGate’s LuCED test creates automated 3D images of cells in sputum, essentially taking a CT scan of individual cells. Once a 3D image is created, a smart computer program (algorithm) determines normal from abnormal cells, allowing for earlier disease detection. Although the CT scan has been around since 1970, this is the first time an individual cell has been able to be viewed in 3D – a capability of LuCED with more than 125 patents surrounding its development.

Phoenix, US
29 (est)

VisionGate Locations

Phoenix, US

VisionGate Metrics

VisionGate Summary

Founding Date


Total Funding

$21.7 M